StockSelector.com
  Research, Select, & Monitor Thursday, November 23, 2017 10:04:17 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
UBS AG$17.20$.09.53%

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  UBS AG vs Drug Manufacturers/Other

UBS Group AG engages in providing financial services to private, corporate and institutional clients. It offers retail banking, corporate and institutional banking, wealth management, asset management, and investment banking. The company's Wealth Management division offers investment management, estate planning, and corporate finance advice, as well as specific wealth management products and services. Its Retail & Corporate division offers financial products and services to retail, corporate, and institutional clients. This division also provides professional services, including fund set-up, accounting, and reporting for traditional investment funds and alternative funds. The company's Investment Bank division is engaged in the sales, trading, and market-making activities across a range of securities; and provides advisory services and access in capital markets. UBS Group AG is headquartered in Zurich, Switzerland.




Engaged in the discovery, development, and commercialization of innovative pharmaceuticals for the treatment of many diseases, either directly or indirectly. Directly treating a disease would involve some sort of drug that could attack the infection itself. An indirect treatment may involve a drug that's used to enhance the body's own antibody production so those antibodies can attack the infection themselves. Not only do some of these companies develop drugs for human use, a good number of them also work on animal or plant diseases as well.
 Totals Company Industry
  Sales: $36,277.7 Mil $100,273.0 Mil
  Market Cap: $66,012.6 Mil $371,597.6 Mil
  Analysts Recommendation: Buy Buy

 Averages Company Industry
 Growth
  Historic Revenue: (6.2%) 45.6%
  Estimated Revenue: N/A 72.8%
  Historic Earnings: (50.0%) (53.7%)
  Estimated Earnings: 41.4% (22.8%)
  Stock Price (1 Year): 9.0% 88.0%
  Cash per Share: (1.5%) (2.4%)
  Dividend: N/A N/A
 Price
  Trailing PE: N/A N/A
  Forward PE: 10.8 22.8
  Price-to-Sales: 1.8 N/A
  Price-to-Book: 1.2 6.1
  Dividend Yield: N/A N/A
  Market Cap: $66,012.6 Mil $12,386.6 Mil
  Operations
  Net Margin: 11.9% (278.0%)
  Gross Margin: 97.7% 83.2%
  Return on Equity: .1 (.5)
  Return on Assets: .0 (.2)
  Balance Sheet
  Current Ratio: 1.1 6.2
  Quick Ratio: 1.1 6.0
  Cash Ratio: .6 5.3
  Debt-to-Equity: 16.2 4.1
  Interest Coverage: .0 2.2
 Technicals
  Relative-Strength Index: 54.8 N/A

 Other companies in Drug Manufacturers/Other Price Market Cap
  Novo Nordisk A\/S  (NVO) $51.84 $128,013.7 Mil
  Allergan plc  (AGN) $174.83 $58,305.8 Mil
  Vertex Pharmaceuticals Inc.  (VRTX) $147.04 $36,799.4 Mil
  Alexion Pharmaceuticals, Inc.  (ALXN) $107.60 $24,210.0 Mil
  BioMarin Pharmaceutical, Inc.  (BMRN) $82.99 $14,531.8 Mil






Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2017 StockSelector.com. All rights reserved.